Savara

Public sources do not name any investment decision-makers at Savara. The firm's website lists no management team or board members, and no principal names are disclosed elsewhere.

Savara is named after the Savara branch of the Altss family, a naming convention that ties the firm's identity directly to a specific family lineage. No detail on its legal structure as a single-family office or other entity type has been published.

Savara's only known investment vehicle is Savara Inc., a public biopharmaceutical company. The firm's focus is on development-stage therapies for rare respiratory diseases, implying a concentration on clinical-stage or approved treatments.

Savara focuses exclusively on rare respiratory disease therapeutics. No other sectors—such as other healthcare verticals, technology, or real assets—are indicated in its public disclosures.

No evidence exists of Savara engaging in co-investments or fund commitments. Its activities appear limited to Savara Inc. as a direct portfolio entity.

The wealth origin is stated as the Altss family, with the firm named for the Savara branch. No further details on the family's business or source of capital are publicly available.